1093 Stock Overview
CSPC Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People’s Republic of China, other Asian regions, the Americas, Europe, and internationally.
No risks detected for 1093 from our risk checks.
CSPC Pharmaceutical Group Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||HK$7.55|
|52 Week High||HK$10.10|
|52 Week Low||HK$6.95|
|1 Month Change||-2.71%|
|3 Month Change||-3.08%|
|1 Year Change||-19.17%|
|3 Year Change||-10.30%|
|5 Year Change||8.50%|
|Change since IPO||1,689.63%|
Recent News & Updates
CSPC Pharmaceutical Group (HKG:1093) Could Easily Take On More Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
CSPC Pharmaceutical Group (HKG:1093) Will Pay A Larger Dividend Than Last Year At CN¥0.10
CSPC Pharmaceutical Group Limited's ( HKG:1093 ) dividend will be increasing from last year's payment of the same...
|1093||HK Pharmaceuticals||HK Market|
Return vs Industry: 1093 exceeded the Hong Kong Pharmaceuticals industry which returned -36.6% over the past year.
Return vs Market: 1093 exceeded the Hong Kong Market which returned -28% over the past year.
|1093 Average Weekly Movement||5.5%|
|Pharmaceuticals Industry Average Movement||5.9%|
|Market Average Movement||6.4%|
|10% most volatile stocks in HK Market||12.5%|
|10% least volatile stocks in HK Market||3.1%|
Stable Share Price: 1093 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: 1093's weekly volatility (5%) has been stable over the past year.
About the Company
CSPC Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People’s Republic of China, other Asian regions, the Americas, Europe, and internationally. The company operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. It provides NBP soft capsules and injections for acute ischemic stroke; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Enxi to treat adult idiopathic Parkinson’s disease; Duomeisu for lymphoma, multiple myeloma, ovarian and breast cancers, and other malignant tumors; Jinyouli to prevent leucopenia and infection induced by chemotherapy; and Keaili for breast cancer.
CSPC Pharmaceutical Group Fundamentals Summary
|1093 fundamental statistics|
Is 1093 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|1093 income statement (TTM)|
|Cost of Revenue||CN¥7.71b|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||0.46|
|Net Profit Margin||18.58%|
How did 1093 perform over the long term?See historical performance and comparison
2.5%Current Dividend Yield
Is 1093 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 4/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 1093?
Other financial metrics that can be useful for relative valuation.
|What is 1093's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does 1093's PE Ratio compare to its peers?
|1093 PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
3692 Hansoh Pharmaceutical Group
1177 Sino Biopharmaceutical
874 Guangzhou Baiyunshan Pharmaceutical Holdings
3320 China Resources Pharmaceutical Group
1093 CSPC Pharmaceutical Group
Price-To-Earnings vs Peers: 1093 is expensive based on its Price-To-Earnings Ratio (15x) compared to the peer average (11.7x).
Price to Earnings Ratio vs Industry
How does 1093's PE Ratio compare vs other companies in the HK Pharmaceuticals Industry?
Price-To-Earnings vs Industry: 1093 is expensive based on its Price-To-Earnings Ratio (15x) compared to the Hong Kong Pharmaceuticals industry average (8.8x)
Price to Earnings Ratio vs Fair Ratio
What is 1093's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||15x|
|Fair PE Ratio||15.2x|
Price-To-Earnings vs Fair Ratio: 1093 is good value based on its Price-To-Earnings Ratio (15x) compared to the estimated Fair Price-To-Earnings Ratio (15.2x).
Share Price vs Fair Value
What is the Fair Price of 1093 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 1093 (HK$7.55) is trading below our estimate of fair value (HK$17.65)
Significantly Below Fair Value: 1093 is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.
Discover undervalued companies
How is CSPC Pharmaceutical Group forecast to perform in the next 1 to 3 years based on estimates from 26 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 1093's forecast earnings growth (11.6% per year) is above the savings rate (1.6%).
Earnings vs Market: 1093's earnings (11.6% per year) are forecast to grow slower than the Hong Kong market (17.1% per year).
High Growth Earnings: 1093's earnings are forecast to grow, but not significantly.
Revenue vs Market: 1093's revenue (11.3% per year) is forecast to grow faster than the Hong Kong market (9.8% per year).
High Growth Revenue: 1093's revenue (11.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 1093's Return on Equity is forecast to be low in 3 years time (17.8%).
Discover growth companies
How has CSPC Pharmaceutical Group performed over the past 5 years?
Past Performance Score2/6
Past Performance Score 2/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 1093 has high quality earnings.
Growing Profit Margin: 1093's current net profit margins (18.6%) are lower than last year (22.6%).
Past Earnings Growth Analysis
Earnings Trend: 1093's earnings have grown significantly by 21% per year over the past 5 years.
Accelerating Growth: 1093's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 1093 had negative earnings growth (-6.8%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (3.7%).
Return on Equity
High ROE: 1093's Return on Equity (19.1%) is considered low.
Discover strong past performing companies
How is CSPC Pharmaceutical Group's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: 1093's short term assets (CN¥22.8B) exceed its short term liabilities (CN¥8.5B).
Long Term Liabilities: 1093's short term assets (CN¥22.8B) exceed its long term liabilities (CN¥964.1M).
Debt to Equity History and Analysis
Debt Level: 1093 has more cash than its total debt.
Reducing Debt: 1093's debt to equity ratio has reduced from 9.7% to 1.3% over the past 5 years.
Debt Coverage: 1093's debt is well covered by operating cash flow (1551.9%).
Interest Coverage: 1093 earns more interest than it pays, so coverage of interest payments is not a concern.
Discover healthy companies
What is CSPC Pharmaceutical Group current dividend yield, its reliability and sustainability?
Dividend Score 3/6
Cash Flow Coverage
Current Dividend Yield
Dividend Yield vs Market
|CSPC Pharmaceutical Group Dividend Yield vs Market|
|Company (CSPC Pharmaceutical Group)||2.5%|
|Market Bottom 25% (HK)||3.0%|
|Market Top 25% (HK)||8.9%|
|Industry Average (Pharmaceuticals)||2.9%|
|Analyst forecast in 3 Years (CSPC Pharmaceutical Group)||2.4%|
Notable Dividend: 1093's dividend (2.52%) isn’t notable compared to the bottom 25% of dividend payers in the Hong Kong market (2.98%).
High Dividend: 1093's dividend (2.52%) is low compared to the top 25% of dividend payers in the Hong Kong market (8.85%).
Stability and Growth of Payments
Stable Dividend: 1093's dividend payments have been volatile in the past 10 years.
Growing Dividend: 1093's dividend payments have increased over the past 10 years.
Earnings Payout to Shareholders
Earnings Coverage: With its reasonably low payout ratio (36%), 1093's dividend payments are well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its reasonable cash payout ratio (50.8%), 1093's dividend payments are covered by cash flows.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Cuilong Zhang (53 yo)
Mr. Cuilong Zhang has been the Vice Chairman of CSPC Pharmaceutical Group Ltd since May 21, 2019 and serves as its Chief Executive Officer since May 27, 2022. He was Rotating Chief Executive Officer of CSP...
CEO Compensation Analysis
|Cuilong Zhang's Compensation vs CSPC Pharmaceutical Group Earnings|
|Date||Total Comp.||Salary||Company Earnings|
|Jun 30 2022||n/a||n/a|
|Mar 31 2022||n/a||n/a|
|Dec 31 2021||CN¥9m||CN¥693k|
|Sep 30 2021||n/a||n/a|
|Jun 30 2021||n/a||n/a|
|Mar 31 2021||n/a||n/a|
|Dec 31 2020||CN¥9m||CN¥693k|
|Sep 30 2020||n/a||n/a|
|Jun 30 2020||n/a||n/a|
|Mar 31 2020||n/a||n/a|
|Dec 31 2019||CN¥7m||CN¥693k|
|Sep 30 2019||n/a||n/a|
|Jun 30 2019||n/a||n/a|
|Mar 31 2019||n/a||n/a|
|Dec 31 2018||CN¥4m||CN¥298k|
Compensation vs Market: Cuilong's total compensation ($USD1.26M) is above average for companies of similar size in the Hong Kong market ($USD926.98K).
Compensation vs Earnings: Cuilong's compensation has been consistent with company performance over the past year.
Experienced Management: 1093's management team is considered experienced (3 years average tenure).
Experienced Board: 1093's board of directors are considered experienced (8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
|01 Apr 22||BuyHK$1,999,863||Kin Man Chak||Individual||3,840,000||HK$0.52|
|01 Apr 22||BuyHK$8,850,002||Qingxi Wang||Individual||3,000,000||HK$2.95|
|26 Nov 21||BuyHK$16,510,004||Dongchen Cai||Individual||2,000,000||HK$8.26|
|24 Nov 21||BuyHK$8,009,998||Dongchen Cai||Individual||1,000,000||HK$8.01|
|23 Nov 21||BuyHK$48,319,194||Dongchen Cai||Individual||6,000,000||HK$8.05|
|Owner Type||Number of Shares||Ownership Percentage|
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
CSPC Pharmaceutical Group Limited's employee growth, exchange listings and data sources
- Name: CSPC Pharmaceutical Group Limited
- Ticker: 1093
- Exchange: SEHK
- Founded: 1992
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: HK$89.962b
- Shares outstanding: 11.92b
- Website: https://www.cspc.com.hk
Number of Employees
- CSPC Pharmaceutical Group Limited
- No. 226 Huanghe Street
- Hebei Province
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|CHJT.F||OTCPK (Pink Sheets LLC)||Yes||Ordinary Shares||US||USD||Jun 1994|
|1093||SEHK (The Stock Exchange of Hong Kong Ltd.)||Yes||Ordinary Shares||HK||HKD||Jun 1994|
|CVG||DB (Deutsche Boerse AG)||Yes||Ordinary Shares||DE||EUR||Jun 1994|
|1093||SHSC (Stock Exchange of Hong Kong Limited - Shanghai - Hong Kong Stock Connect)||Yes||Ordinary Shares||HK||HKD||Jun 1994|
|1093||SZSC (The Stock Exchange of Hong Kong - Shenzhen - Hong Kong Stock Connect)||Yes||Ordinary Shares||HK||HKD||Jun 1994|
|1093 N||BMV (Bolsa Mexicana de Valores)||Yes||Ordinary Shares||MX||MXN||Jun 1994|
|CSPC.Y||OTCPK (Pink Sheets LLC)||UNSPON ADS EACH REP 4 ORD SHS||US||USD||May 2018|
|CVGU||DB (Deutsche Boerse AG)||UNSPON ADS EACH REP 4 ORD SHS||DE||EUR||May 2018|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/09/29 00:00|
|End of Day Share Price||2022/09/29 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.